Tocilizumab for giant cell arteritis

CONCLUSIONS: This review indicates that tocilizumab therapy may be beneficial in terms of proportion of participants with sustained remission, relapse-free survival, and the need for escape therapy. While the evidence was of moderate certainty, only two studies were included in the review, suggesting that further research is required to corroborate these findings. Future trials should address issues related to the required duration of therapy, patient-reported outcomes such as quality of life and economic outcomes, as well as the clinical outcomes evaluated in this review.PMID:35560150 | PMC:PMC9105486 | DOI:10.1002/14651858.CD013484.pub3
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research